Mara Dottore

Frome Road
Adelaide, SA 5001, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.

Journal: Blood

Published: December 09, 2024

Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.

Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.

Journal: Blood

Published: December 09, 2024

Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia.

Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia.

Journal: Cancer discovery

Published: December 13, 2022

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.

Journal: EMBO reports

Published: June 10, 2021

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.

Journal: Science advances

Published: February 22, 2018

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.

Journal: Nature communications

Published: July 04, 2017

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Journal: Blood advances

Published: November 10, 2016

Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling.

Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling.

Journal: Structure (London, England : 1993)

Published: May 02, 2016

CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.

CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.

Journal: mAbs

Published: December 15, 2015

Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.

Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.

Journal: Cell reports

Published: February 10, 2014

High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Journal: PloS one

Published: June 03, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026